OncoMatch/Clinical Trials/NCT06530251
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Is NCT06530251 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for hepatocellular carcinoma.
Treatment: AK112 · Cadonilimab · AK127 · AK130 · Sintilimab · Bevacizumab biosimilar — There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination therapy or monotherapy in the treatment of HCC compared to the combination of Sintilimab and Bevacizumab biosimilar.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C (BCLC)
Grade: Child Pugh Grade A (Child Pugh)
Barcelona Clinical Liver Cancer (BCLC) stage B or C. Liver function grading Child Pugh Grade A.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
Previously received immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, and any other treatments targeting the immune mechanisms of tumors.
Cannot have received: local treatment for the liver
Exception: allowed if >4 weeks prior to first administration
Received local treatment for the liver within 4 weeks prior to the first administration
Cannot have received: palliative radiotherapy for non liver patients
Exception: allowed if >2 weeks prior to initial administration
Received palliative radiotherapy for non liver patients within 2 weeks prior to initial administration
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
Child Pugh Grade A
Has adequate organ function. Liver function grading Child Pugh Grade A.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify